盐酸缬更昔洛韦片适应症

, developed by the Swiss company Roche, is an oral anti-cytomegalovirus infection drug. What are its indications?

In May 2001, the U.S. FDA approved the marketing of Valcyte hydrochloride tablets for clinical use in the treatment of acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome.

In May 2003, its indications were expanded to include Valcyte for the prevention and treatment of secondary CMV infection in organ transplant recipients.

On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved valganciclovir hydrochloride tablets (Valcyte) for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

Launched in China in 2006, it is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

Usage and dosage: 1. Induction treatment of CMV retinitis. For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. 2. Maintenance treatment of CMV retinitis. After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. 3. Prevention of CMV infection in transplant patients. For kidney transplant patients, the recommended dose of valganciclovir hydrochloride tablets is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Special note: Do not break or smash. Considering that valganciclovir hydrochloride tablets have potential teratogenic and carcinogenic effects in humans, special caution should be used when handling damaged tablets. Avoid direct contact with skin or mucous membranes with broken or crushed tablets. In the event of contact, flush skin thoroughly with soap and water and eyes with plenty of water.